contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


faron-phase-iii-bexmab-trial-patient-enrollment-completed-topline-readout-postponed-to-april

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Faron Pharmaceuticals is a medical technology company. The company conducts research and development of therapeutic solutions used for the treatment of immune diseases and various organ damage. The largest operations are in North America and Europe, with hospitals and research institutes as the dominant customer base. In addition to the main business, various value-added services are offered. The head office is located in Turku. 

Faron Pharmaceuticals

Faron announced that it has identified the last patient for the Phase II BEXMAB study and now expects the topline readout in April. As a result, patient enrollment was completed in January as previously announced, although the topline response rate readout was bumped slightly forward from the end of Q1'25 as previously announced.

Translation: Original published in Finnish on 1/31/2025 at 4:11 pm EET.
Faron <a href="https://www.inderes.se/releases/final-patient-identified-for-the-bexmab-study">announced</a> that it has identified the last patient for the Phase II BEXMAB study and now expects the topline readout in April. As a result, patient enrollment was completed in January as previously announced, although the topline response rate readout was bumped slightly forward from the end of Q1&apos;25 as previously announced.
<h2>The financing solution is tilting towards equity financing</h2>
According to the company, Faron has sufficient cash resources for the end of Q2&apos;25. Without breaching the terms of the loan, cash will be sufficient until the end of Q1&apos;25 at the latest when additional financing will be required. We believe that a partnership agreement or an equity financing round are the most likely financing options for the company. We expect Faron to seek a partnership agreement only after the topline readout, and it being postponed tips the scales more clearly in favor of equity financing. Supported by the positive results of the BEXMAB trial to date, the company is in a good position to raise funds, so we do not see any particular concerns. We will review our view of the company no later than the time of the publication of the financial statements at the end of February.

Inderes

Faron Phase I/II BEXMAB trial patient enrollment completed; topline readout postponed to April

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Valuation methods: DCF model

Valuation methods: Valuation multiples

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.

	2023	24e	25e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-28.6	-26.1	-29.2
EBIT-% (adj.)	-714,200.00 %	-653,250.00 %	-730,500.00 %
EPS (adj.)	-0.45	-0.28	-0.30
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	-	-	-
EV/EBITDA	-	-	-

The financing solution is tilting towards equity financing

Faron Pharmaceuticals

Key Estimate Figures11.12.2024